Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study

Hepatology

Volumn 52, Issue 6, 2010, Pages 2065-2076

  Reuben, Adrian ^a   Koch, David G ^a   Lee, William M ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BILIRUBIN;

ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; ANTIMETABOLITES; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 78649625452     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23937     Document Type: Article

References (54)

1. Public Citizen's Health Research Group.Worst pills, best pills. Adverse drug reactions. Accessed September 2010.
2. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. The importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363-1369.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
4. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117.
5. Zimmerman H. Drug Hepatotoxicity. 2nd ed. Philadelphia: Lippincott; 1999.
6. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-155.
7. Larrey D. Hepatotoxicity of herbal medicines. J Hepatol 1997; 26( Suppl): 47-51.
8. Crombie DL. Monitoring adverse drug reactions. J R Coll Gen Pract 1975; 25: 337-343.
9. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999; 319: 1541.
10. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. HEPATOLOGY 2002; 36: 451-455.
11. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-controlled study. Br J Clin Pharmacol 2004; 58: 71-88.
12. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Commission on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-138.
13. Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute non-fulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005; 39: 64-67.
14. Whitehead MW, Hainsworth I, Kingham JGC. The causes of obvious jaundice in South West Wales. Gut 2001; 48: 409-413.
15. Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millenium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86-94.
16. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005; 42: 481-489.
17. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced injury in the United States. Liver Transpl 2004; 10: 1018-1023.
18. Björnsson E, Jerlstad P, Bergqvist A. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-1101.
19. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
20. Larrey D, Pageaux G-P. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 2005; 17: 141-143.
21. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al.; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
22. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al.; Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137: 856-864.
23. Kamath PS, Kim WR; the Advanced Liver Disease Study Group. The Model for End-Stage Liver Disease (MELD). HEPATOLOGY 2007; 45: 799-805.
24. U.S. Food and Drug Administration. Warning on Hydroxycut Products. Accessed September 2010.
25. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-445.
26. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al.; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter prospective study. HEPATOLOGY 2005; 42: 1364-1372.
27. Wei G, Kalaitzakis E, Bergquist A, Björnsson E. Long-term follow-up of patients with acute liver failure of indeterminate aetiology. Scand J Gastroenterol 2008; 43: 984-991.
28. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
29. Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007; 262: 393-401.
30. Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 1985; 60: 289-292.
31. Schilsky ML, Scheinberg IH, Sternlieb I. Hepatic transplantation for Wilson's disease: indications and outcome. HEPATOLOGY 1994; 19: 583-587.
32. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey. Patterns of Prescription Drug Use in the United States, 1988-94. Accessed September 2010.
33. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998; 43: 1311-1316.
34. Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33-38.
35. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
36. Kaplowitz N. Chapter 1. Drug-Induced liver disease. In: Kaplowtiz N, DeLeve LD, eds. Drug-Induced Liver Disease. 2nd ed. New York: Informa Healthcare; 2007: 1-11.
37. U.S. Census Bureau. Profiles of General Demographic Characteristics, 2000. Accessed September 2010.
38. Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, et al. Etiology and outcome of 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 29-34.
39. Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007; 25: 1411-1421.
40. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32( Suppl. 1): 77-78.
41. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, et al.; Acute Liver Failure Study Group. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. HEPATOLOGY 2007; 46: 1436-1442.
42. Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al.; Acute Liver Failure Study Group. Measurement of serum acetaminophen protein adducts in patients with acute liver failure. Gastroenterology 2006; 130: 687-694.
43. Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007; 13: 329-340.
44. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13: 6608-6611.
45. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-143.
46. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequences and contributor. Chem Biol Interact 2004; 150: 35-51.
47. Wright C 4th, Vafier JA, Lake CR. Disulfiram-induced fulminating hepatitis: guidelines for liver-panel monitoring. J Clin Psychiatry 1988; 49: 430-434.
48. Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2008; 23: 366-373.
49. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374-1380.
50. Molden E, Westergren T. Interaction risk with statin switch. [In Norwegian] Tidsskr Nor Laegeforen 2007; 127: 428-431.
51. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14-19.
52. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.
53. Li B, Wang Z, Fang JJ, Xu CY, Chen WX. Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol 2007; 13: 628-623.
54. Rutherford A, Davern T, Hay JE, Murray NG, Hassanein T, Lee WM, et al.; Acute Liver Failure Study Group. Influence of high body mass index on the outcome in acute liver failure. Clin Gastroenterol Hepatol 2006; 4: 1544-1549.